// App-Quantinova.ai

e20516 : First-line CyborD treatment for graft ineligible multiple myeloma patients: Real-life efficacy and tolerability.

Researchers

Presenter

  • Dominic Duquette

Principal Investigators

  • Marie-Michelle Germain

Medical Centers

  • CHU de Quebec Hopital de l'Enfant-Jesus, Quebec, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved